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Abstract 
 
Gliobastoma (Grade IV Astrocytoma) is an aggressive, malignant brain 
neoplasm and is the most recurrent malignant tumor in adult humans. Existing 
therapies for glioblastoma (GBM) include, among others, neurosurgery, 
chemotherapy, radiotherapy and systemic antineoplastic therapy. However, high 
mortality and low survival rates are associated with this disease largely due to poor 
prognosis, poor understanding of the nature of the disease and the lack of efficient 
therapies. Hence, more selective and efficient approaches for targeting GBM are 
urgently needed. In this study we attempt to take advantage of the potential arginine 
auxotrophy of GBM cells to selectively target them using recombinant human 
Arginase I cobalt [HuArgI(Co)] coupled with polyethylene glycol 5000 [HuArgI 
(Co)-PEG5000]. 
The human form of the enzyme namely human L-arginase I (hArgI) uses two 
manganese ions as cofactors. To improve the catalytic activity of the enzyme, 2 
Cobalt ions (Co
2+
) have been used to substitute the manganese ions in the active site 
of the enzyme. The resulting HuArgI (Co) was conjugated to polyethylene glycol to 
generate the pegylated, Cobalt-substituted recombinant human arginase [HuArgI 
(Co)-PEG5000]. 
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Cytotoxicity of HuArgI (Co)-PEG5000 was tested on a panel of 9 human 
GBM cell lines using a proliferation inhibition assay. HuArgI (Co)-PEG5000-
induced arginine depletion was cytotoxic to all the GBM cell lines tested with IC50 
values ranging between 128 to 985 pM and a percent cell kill at highest 
concentration > 75%. Addition of excess L-citrulline failed to rescue GBM cells 
from arginine depletion-induced cytotoxicity indicating complete arginine 
auxotrophy of GBM cells. Time course analysis revealed that peak toxicity is 
observed after an incubation time of 48 to 72 h. Sensitivity of GBM cells to HuArgI 
(Co)-PEG5000-induced arginine depletion as well as the impact of addition of L-
citrulline on cell sensitivity, were dependent on expression levels of 
argininosuccinate synthetase-1 (ASS-1), the enzyme whose activity leads to the 
synthesis of arginine in cells. Cell cycle analysis showed that arginine depletion, in 
GBM cells, does not induce cell cycle arrest and confirm the cytotoxic response of 
these cells to arginine deprivation. AnnexinV/PI and caspase staining showed an 
increase in the percentage of cells staining positively with annexinV and negatively 
with PI, in one of the cell lines tested, an indication that HuArgI (Co)-PEG5000-
mediated arginine depletion may induce apoptotic cell death in GBM cells. 
In this study we demonstrate that GBM cells are auxotrophic for arginine and are, 
subsequently, sensitive to the HuArgI (Co)-PEG5000-mediated arginine depletion. 
Arginine depletion is therefore, a potential novel, targeted therapy for GBM. 
Keywords: Glioblastoma, Arginine depletion, HuArgI (Co)-PEG5000, Arginine 
auxotrophy, Cytotoxicity. 
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GLOSSARY 
GBM: Glioblastoma. 
HuArgI (Co)-PEG5000: pegylated cobalt-substituted recombinant human arginase. 
IDH: isocytrate dehydrogenase. 
TIC: tumor initiating cells. 
RTK: receptor tyrosine kinase. 
PI3K: phosphatidylinositol-3-OH kinase. 
EGFR: epidermal growth factor receptor. 
PDGFR: platelet derived growth factor receptor. 
MAPK : mitogen activated-protein kinase. 
GBM-SCs: glioblastoma stem cells. 
 IL13-PE38: Interleukin-13 receptor-targeted cytotoxin. 
IL-4(38-37)-PE38KDEL: Interleukin-4 receptor-targeted cytotoxin. 
siRNA: small interfering RNA. 
GTPases: guanosine triphosphatases. 
ALL: acute lymphoid leukemia. 
AML: acute myeloid leukemia. 
HCC: hepatocellular carcinoma. 
PC: pancreatic carcinoma. 
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T-ALL: lymphoblastic T cell leukemia. 
ASS: argininosuccinate synthetase. 
ASL: argininosuccinate lyase. 
hARGI: human l-arginase I. 
ADI: arginine deiminase. 
OTC: ornothine trancarbamylase. 
MM: malignant melanoma. 
FBS: fetal bovine serum. 
DMEM: Dulbecco's modiﬁed Eagle's medium. 
PI: propidium iodide. 
RFI: ratio of fluorescence intensity. 
MFI: mean fluorescence intensity. 
IC50: inhibitory concentration.
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CHAPTER ONE 
INTRODUCTION 
 The limitations of existing cancer therapeutic strategies such as 
chemotherapy, radiation therapy and surgery have been reached. These limitations 
are one of the main underlying factors of the poor prognosis and low survival rates 
of a number of tumor types, including glioblastoma (GBM), hence the need for 
developing novel, tumor-targeted therapeutic strategies.  
1.1- Glioblastoma 
Glioblastoma multiforme (GBM) is an aggressive, malignant brain neoplasm 
which corresponds to grade IV astrocytoma that possibly arises from genetic and 
epigenetic modifications in normal astroglial cells (Haque, Banik & Ray, 2011). 
GBMs are subdivided into primary and secondary GBM. Primary GBMs arise from 
de novo cells without any previous low-grade disease (Furnari et al. 2007), while 
secondary GBMs are derived from grade II or III gliomas and are histologicaly 
indiscernible from primary GBM, however they may be molecularly different. 
Secondary GBMs present a mutation in the isocitrate dehydrogenase (IDH)1 and 
IDH2 genes in more than 80% of the cases (Galli et al. 2004).  
In GBM, the fast growing cancerous cells lead to the development of tumors 
in a period of few weeks in which the malignant transformation of cells begins 
following the accumulation of mutations in neural progenitor cells that give rise to 
cancerous gliomas (Galli et al. 2004). Such tumor initiating cells (TICs) are known 
as glioma-propagating cells and represent a small population that is responsible for 
all brain tumor cell types and are the most resistant to treatment (Chesler, Berger & 
Quinones-Hinojosa, 2012). Signaling pathways involved in GBM are mainly 
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pathways for cell proliferation, apoptosis, senescence, migration and cell-to-cell 
communication (Preusser et al. 2011). Molecular amplification and mutational 
activation of the receptor tyrosine kinase (RTK) genes, activation of the 
phosphatidylinositol-3-OH kinase (PI3K) pathway and inactivation of p53 and 
retinoblastoma suppressor gene pathways (Furnari et al. 2007), have been implicated 
in more than 80% of GBMs (Preusser et al. 2011). Particularly, GBMs overexpress 
the oncogenes EGFR and PDGFR (RTKs), and show mutations and deletions in 
PTEN and TP53 tumor suppressor genes activating the P13K/Akt and Ras/MAPK 
pathways (Mischel & Cloughessi, 2003). 
1.2- Clinical manifestation 
The clinical manifestation of GBM depends mainly on the location and size 
of the tumor. Frequent symptoms include: aphasia, hemiparesis, nausea, vomiting, 
paresthesia, visual, mood and personality disturbances and seizures in addition to 
headaches, all of which are signs of increased pressure in the intracranial region. 
  GBM is associated with low survival rates where newly diagnosed patients 
have an average survival median of approximately one year (Mischel & Cloughessi, 
2003). The high mortality rates are mainly due to poor prognosis, little knowledge 
about the nature of the disease and poor therapeutic approaches. Recent studies, in 
GBM, have shown the presence of a population of cells that mimic adult stem cells 
in self-renewal capability and have the ability to survive chemo-radiotherapy 
treatments. Such cells are classified as cancer stem cells (GBM-SCs). In addition to 
rapid proliferation rates and tumor accessibility, these stem cells are thought to be 
associated with the poor prognosis and treatment resistance of this cancer (Maugerri-
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Sacca, Di Martino & De Maria, 2013). For these reasons, available therapies can 
only prolong patients' lives up to one year and rarely beyond two years (Lo, 2010).  
 1.3- GBM Therapies 
Therapies for newly diagnosed GBM include neurosurgery, radiotherapy, 
systemic antineoplastic therapy and Carmustine Wafers in which a cytotoxic 
molecule, carmustine, is placed within the tumor (Preusser et al. 2011).  
A different approach involved the use of a recombinant protein, Interleukin-
13 receptor-targeted cytotoxin (IL13-PE38), in combination with irradiation to treat 
glioblastoma cells. This treatment proved to be very efficacious on a number of 
glioblastoma cell lines. Administrating IL13-PE38 to cells previously irradiated did 
not enhance cytotoxicity, only simultaneous administration of both therapies proved 
to be cytotoxic against these cells. (Kawakami, Kawakami, Liu & Puri, 2005). 
Another fusion toxin, namely IL-4(38-37)-PE38KDEL, which consists of 
circularly permuted IL-4 bound to a truncated Pseudomonas aeruginosa exotoxin A, 
was found to be cytotoxic to IL-4R bearing glioblastoma cells. When administered 
locally into right frontal lobes of rats, IL4(38-37)-PE38KDEL induced necrosis at 
nontoxic levels and intrathecal administration in monkeys showed no systemic 
toxicity. Since normal brain tissue expresses low levels of IL-4R, this fusion toxin 
proved to be effective against malignant astrocytoma (Puri et al. 1996). 
In other studies, new therapeutic approaches included the use of microRNAs 
in many therapies targeting the TICs subpopulation of GBMs whereby microRNAs 
have been shown to have a potential role in the GBM apoptotic pathway (Liu, 
Albrecht, Ni, Yang & Li, 2013), cellular proliferation, stemness maintenance, 
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migration/invasion pathways among others. Nonetheless, this strategy is still limited 
by the identification and isolation of GBM-SCs (Chu et al. 2012). 
Other recent studies sought to decrease tumor's resistance to therapy by 
inhibiting the low voltage gated type T calcium channels involved in embryonic cell 
proliferation and differentiation which are often over expressed in tumors including 
GBM.  Silencing the T-type Ca
2+ 
channels by selective inhibitors or by siRNA-
mediated knock down reduced cell viability and induced apoptosis in GBM cells 
(Valerie et al. 2013). 
 
1.4- Autophagy Contribution in Anti-Cancer Therapies 
  Most recently, mechanisms within the tumor cells have been the scope of 
various studies for their potential contribution to anti-tumor therapeutics. Once such 
process, that is being extensively studied is autophagy. Autophagy is an intracellular 
mechanism that involves the sequestration of organelles and cytoplasmic 
constituents in an autophagosome, a double-membrane vesicle, followed by 
complete degradation and ultimate recycling of the macromolecules in the lysosome 
(Mizushima, 2007). Such process is regulated by different kinases, guanosine 
triphosphatases (GTPases) and phosphatases and is thought to relieve the cell from 
different stress conditions (Klionsky, 2000; Yang, 2009). Autophagy plays an 
important role during cellular development, differentiation, adaptive and innate 
immunity, among others (Yang & Klionsky, 2009). In more recent studies, 
autophagy has been investigated for its potential role in cancer. It is suspected that 
autophagy increases the cancer cells’ resistance to chemotherapy and radiotherapy 
and thus promotes tumorigenesis. Despite evidence supporting such hypothesis, the 
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contribution of autophagy to cancer treatments is still controversial as evidence 
supporting the tumor suppression role of autophagy has been demonstrated (Chen et 
al. 2010). 
 
1.5- The Need of Novel Targeted Therapies 
Thus, despite all available therapies, patients with GBM experience 
recurrence and eventually die from their disease. For these reasons novel, tumor-
selective therapeutic approaches are needed to improve the treatment and extend 
patients' survival chances (Marosi, 2011). We and others have been investigating the 
use of arginine depletion (using either a pegylated recombinant human arginase or 
the recombinant bacterial enzyme arginine deiminase) as a potential targeted therapy 
against a number of tumor types, including acute lymphoid leukemia (ALL), acute 
myeloid leukemia (AML), hepatocellular carcinoma and pancreatic carcinoma.   
 
1.6- Arginine Deprivation as Potential Therapy 
In cells, arginase hydrolyses the amino acid L-arginine into L-ornithine and 
urea (Hernandez et al. 2010). L-arginine is considered a semi-essential amino acid 
since it is not only acquired through diet and muscle catabolism, but also through 
endogenous production in somatic cells where the urea cycle enzymes 
argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL) catalyzes the 
conversion of citrulline into arginine (Manca et al. 2011). The use of arginase as a 
potential tumor-targeted approach is based on the fact that some cancer cells were 
shown to be completely auxotrophic for arginine, due to mutations in ASS and thus 
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depleting arginine in the tumor environment was shown to selectively induce 
decreased proliferation and apoptosis in tumor cells (figure 1). 
 
Figure 1. Enzymes and Intermediates of the urea cycle in both bacterial and 
mammalian cells. In bacterial cells Arginine is cleaved by ADI to citrulline and NH3 
while in mammalian cells Arginine is cleaved by arginase to ornithine and urea. 
 
Arginase-induced depletion of extracellular arginine showed significant 
improvement in the treatment of lymphoblastic T cell leukemia (T-ALL), 
hepatocellular carcinoma (HCC) and pancreatic carcinoma (Hernandez et al. 2010; 
Glazer et al. 2011.). The enzyme depleted L-arginine levels in malignant T-ALL cell 
lines and in mice with T-ALL tumors, subsequently impairing proliferation and 
leading to a decreased cell cycle activity and apoptosis induction. (Hernandez et al. 
7 
 
2010). Similarly, arginase induced apoptosis in HCC and PC cell lines with an 
increase in caspase-3 activity in addition to autophagy induction which was observed 
both in vivo and in vitro. (Glazer et al.2011).  
The human form of the enzyme namely human L-arginase I (hArgI) uses two 
manganese ions as cofactors but shows low activity at physiological pH because the 
manganese ions tend to be rapidly lost from the enzyme in serum and thus 
inactivated it (Glazer et al. 2011). To improve the catalytic activity of the enzyme, 2 
Cobalt ions (Co
2+
) have been used to substitute the manganese ions in the active site 
of the enzyme. The use of the cobalt ions showed a stronger electrostatic interaction 
with cationic amino acids and thus increased the affinity of the amino acid to the 
enzyme (D'Antonio & Christianson, 2011). To prolong the enzyme's persistence in 
circulation the HuArgI (Co) was conjugated to polyethylene glycol to generate the 
pegylated, Cobalt-substitute recombinant human arginase [HuArgI (Co)-PEG5000] 
(Glazer et al. 2011). Another pegylated enzyme, namely arginine deiminase (ADI-
PEG) that hydrolyses arginine into citrulline and ammonia in bacteria, have also 
been used in the treatment of malignant melanoma (MM) and hepatocellular 
carcinoma (HCC), and is also thought to interfere the activities of ASS and ornithine 
transcarbamylse (OTC), the latter being responsible for citrulline synthesis (Manca 
et al. 2011).  
The use of pegylated arginase as an effective therapy against MM, HCC and 
T-ALL holds it as a potential therapeutic approach in GBM and this is what this 
study aims to show. To our knowledge, this is the first study to investigate arginine 
auxotrophy in GBM cells and to attempt selective targeting of GBM using HuArgI 
(Co)-PEG5000-induced arginine depletion. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 2.1- Cell Lines and Reagents 
The potency of HuArgI (Co)-PEG5000 was tested on a panel of 9 human 
GBM cell lines: A172, HS683, H4, SF268, SW1088, T98, U118-MG, U87-MG and 
U251. Cells were obtained from the American Type Culture Collection (ATCC) and 
cultured in DMEM media containing 10% heat inactivated FBS and 
Penicillin/Streptomycin at 37°C and 5% CO2. 
Human Arginase I cobalt [HuArgI(Co)] coupled with polyethylene glycol 5000 
[HuArgI (Co)-PEG5000] was manufactured in the laboratories of George Georgiou 
and Everett Stone at the University of Texas in Austin, TX, USA, as described 
previously (Zakalskiy et al, 2011).  
 
2.2- Proliferation Inhibition Assay (cytotoxicity) 
 Sensitivity of GBM cells to HuArgI (Co)-PEG5000, with and without the 
addition of excess exogenous L-citrulline, was determined using a proliferation 
inhibition assay as described previously (Abi Habib et al, 2005). Briefly, aliquots of 
1000 cells/well, in 100 l cell culture medium, were incubated in Costar flat-
bottomed 96-well plates (Corning Inc. Corning, NY). L-citrulline was added to cells 
at a concentration of 1.14 µM. This was followed, after 2 hour incubation, by the 
addition of 50 l HuArgI (Co)-PEG5000 in medium to each well to yield 
concentrations ranging from 10
-7
 to 10
-13
 mol/L after which the plates were 
incubated at 37°C/5% CO2 for 48 or 72 hours. Incubation times of 24, 48, 72, 96 and 
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120 hours were tested to establish the time course. 50 l of XTT cell proliferation 
reagent (Roche, Basel, Switzerland) were then added to each well and the plates 
were incubated for an additional 4 hours. Absorbance at 450nm was then read using 
a microplate reader (Thermo Fisher Scientific, Waltham, MA). Nominal and percent 
average absorbance was plotted against the log of the toxin concentration. Nonlinear 
regression with a variable slope sigmoidal dose-response curve is generated along 
with IC50 using GraphPad Prism software (GraphPad Software, San Diego, CA).  
 
2.3- Cell Cycle Analysis 
 The impact of HuArgI (Co)-PEG5000 treatment on the cell cycle of GBM 
cells was determined using Propidium Iodide (PI)-staining on flow cytometry as 
described previously (Abi Habib et al, 2005). Briefly, cells (10000 cells/well in 100 
µl growth medium) incubated with 3 different concentrations of HuArgI (Co)-
PEG5000 (100000, 3000 and 45 pM) or media alone in flat-bottom 96-well plates 
(Corning Inc. Corning, NY) for 24 and 48 hours at 37
o
C/5% CO2, were harvested 
and fixed in 70% ethanol for a minimum of 24 hours at -20
o
C. Cells were then 
incubated in 500 l PI staining solution (50 µg/ml) for 40 minutes at 37oC. Samples 
were then read on a C6 flow cytometer (BD Accuri, Ann Arbor, MI) and cell DNA 
content was measured on FL2-A. The target cell population, excluding fragments 
and doublets, was gated on width versus forward scatter. Percent of cells in G0/G1, S 
and G2/M phase as well as percent cells in pre-G0/G1 phase (dead) was determined 
in control cells and in cells treated with the different concentrations of HuArgI (Co)-
PEG5000 at the different time points. 
 
10 
 
2.4- Analysis of Cell Death 
The type of cell death was determined using fluorescin Isothiocyanate 
(FITC)-conjugated Annexin V antibody- (Annexin V-FITC) and PI staining 
(apoptosis detection kit, Abcam, Cambridge, MA) as described previously (Abi 
Habib et al. 2005). The presence of active caspases in cells cultured for 24 hours 
with or without HuArgI (Co)-PEG5000 was detected using a cell permeable, FITC-
conjugated active caspase inhibitor (R&D systems) on flow cytometry as described 
previously (Abi Habib et al, 2005). Briefly, 10000 cells/well were plated in 100 l 
media in a flat-bottom 96-well plate and were incubated with either 100 l of media 
alone (control cells) or media containing different concentrations of HuArgI (Co)-
PEG5000 (100000, 3000 and 45 pM) for 24 and 48 hours at 37
o
C/5% CO2. Cells 
were then either harvested and incubated with  FITC-conjugated annexin V antibody 
(2.5 mg/ml) and PI (5 mg/ml) in antibody binding buffer for 45 minutes at 37
o
C  or 
incubated with a FITC-conjugated active caspase inhibitor (ApoStat Apoptosis 
Detection Kit, R&D Systems, Abingdon, England) for 60 minutes then harvested. 
Cells were then read using a C6 flow cytometer (BD Accuri, Ann Arbor, MI). 
Annexin V/PI data was analyzed on FL1-H versus FL2-H scatter plot and caspase 
activation was detected on FL1-H. Unstained cells were used as negative control. 
Cells were gated on width versus forward scatter. Cells had to show positive annexin 
V staining, negative PI staining and positive active caspase staining to be considered 
apoptotic, while cells positive for both annexin V and PI staining and negative for 
active caspase staining were considered non-apoptotic/necrotic. 
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2.5- Autophagy Assays 
The potential role played by autophagy in arginine depletion-induced 
cytotoxicity of GBM cells was tested by incubating GBM cells with HuArgI (Co)-
PEG5000 alone and in combination with the autophagy inhibitor chloroquine. 
Briefly, aliquots of 1000 cells/well, in 100 l cell culture medium, were plated in a 
flat-bottom 96-well plate (Corning Inc. Corning, NY). Chloroquine was added to a 
subset of wells at a fixed concentration of 10 µM  followed by the addition of 50 l 
HuArgI (Co)-PEG5000 in media to each well yielding concentrations ranging from 
10
-7
 to 10
-13
 M after which the plates were incubated for 24 and 48 hours at 37
o
C/5% 
CO2. This was followed by the addition of 50 l XTT cell proliferation reagent 
(Roche, Basel, Switzerland) to each well and the plates were incubated for another 4 
hours. Absorbance was then read at 450 nm using a 96-well plate reader (Thermo 
Fisher Scientific, Waltham, MA). Data was analyzed using GraphPad Prism V 
software (GraphPad Software, San Diego, CA) and the IC50 (inhibitory concentration 
50) of HuArgI (Co)-PEG5000 alone or in the presence of chloroquine were 
compared. 
 
 2.6- Intracellular Staining and Flow Cytometry Analysis 
Expression levels of Argininosuccinate Synthetase 1 (ASS-1) were assessed 
using intracellular staining on flow cytometry as described previously (Kassab et al, 
2013). Approximately 3x10
6
 cells were fixed in 70% ethanol for 15 min. Cells were 
then incubated with a 1/100 dilution of anti-ASS-1 mouse monoclonal antibody 
(Sigma, Danvers, MA) in antibody binding buffer containing 0.05% Triton-X 100, 
for 1 h at 37
o
C, followed by a 30-minute incubation with a 1/100 dilution of a FITC-
12 
 
conjugated rabbit anti-mouse polyclonal antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA). Isotypic control consisted of fixed cells incubated with a 1/100 dilution 
of a mouse IgG and a FITC-conjugated rabbit anti-mouse polyclonal antibody. 
Samples were then washed once in phosphate buffered saline (PBS), re-suspended in 
binding buffer and analyzed using a C6 flow cytometer (BD Accuri, Ann Arbor, 
MI). Cells were gated on width versus forward scatter and ASS-1 staining was 
detected on FL1-H. The presence of ASS-1 was analyzed and compared with that of 
the isotopic control. Positivity for the presence of ASS-1 was determined using the 
ratio of fluorescence intensity (RFI) between the mean fluorescence intensity (MFI) 
of the stained cells and the mean fluorescence intensity of the isotypic control cells. 
An RFI > 2 was considered positive for the expression of ASS-1 while an RFI ≤ 2 
was considered negative. In addition, cells were analyzed on forward scatter versus 
FL1-h to determine the percentage of ASS-1 positive cells. 
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CHAPTER THREE 
RESULTS 
 
3.1- Proliferation Inhibition Assay (cytotoxicity) 
The cytotoxicity of pegylated human recombinant Arginase I cobalt (HuArgI 
(Co)-PEG5000) was tested on a panel of 9 human glioblastoma (GBM) cell lines. 
All the GBM cell lines tested were sensitive to the HuArgI (Co)-PEG5000-mediated 
arginine depletion with IC50 values ranging from 128 to 985 pM and a percent cell 
kill at highest concentration > 75%, at 48 and 72 hours post-treatment, indicating the 
potent cytotoxic effects of HuArgI (Co)-PEG5000-mediated arginine depletion on 
GBM cell lines (Table 1, Figure 2).  
Since cytotoxicity following arginine deprivation may be a time dependent 
process, we tested the effect of increasing incubation times on the cytotoxicity of 
HuArgI (Co)-PEG5000 to GBM cells. Incubation times of 48 and 72 hours revealed 
an increased sensitivity of GBM cell lines to HuArgI (Co)-PEG5000-induced 
arginine depletion compared to 24 hour incubation. Further incubations of 96 and 
120 hours were carried out, but did not show a significant increase in sensitivity 
compared to the 48 and 72 hour incubation times indicating that maximum 
cytotoxicity in GBM cells is attained after 48 to 72 hours of arginine depletion. Time 
course for SF showed similar IC50 values of 159 pM, 224 pM and 240 pM after 72, 
96 and 120 hour incubations, respectively. 
Sensitivity to arginine depletion maybe due to complete arginine auxotrophy 
of tumor cells or to partial arginine auxotrophy coupled to a rapid proliferation rate. 
Several studies have shown that, in cells with partial arginine auxotrophy and rapid 
proliferation rates, addition of excess exogenous L-citrulline is capable of rescuing 
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cells from arginine depletion-induced cytotoxicity by increasing flux through the 
urea cycle resulting in an increase in intracellular arginine levels (Mauldin et al, 
2012). Therefore, the failure of excess exogenous L-citrulline to rescue cells from 
arginine depletion-induced cytotoxicity is considered a marker of irreversible, 
complete arginine auxotrophy.  
 
Table 1. Sensitivity of GBM cell lines to HuArgI (Co)-PEG5000 both in the absence 
and presence of  1.14µM of exogenous L-citrulline. 
 
Cell line HuArgI (Co)-PEG5000 HuArgI (Co)-PEG5000 + L-
citrulline 
U251 128 pM 134 pM 
U87-MG 152 pM 145 pM 
T98 204 pM 751 pM 
HS683 312 pM 347 pM 
SF 325 pM 255 pM 
H4 329 pM 343pM 
U118-MG 442 pM 874 pM 
A172 981 pM 706 pM 
SW1088 985 pM 581 pM 
Addition of L-citrulline, at a concentration of 1.14 µM, failed to reverse the 
cytotoxicity of HuArgI (Co)-PEG5000-induced arginine depletion in GBM cell lines 
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and had no impact on the sensitivity of all but two GBM cell line to HuArgI (Co)-
PEG5000  (U118-MG and T98) whose IC50 values increased by 2 to 3-fold in the 
presence of excess L-citrulline. The remaining 7 cell lines had similar IC50 values in 
the presence and absence of L-citrulline (Table 1, Fig. 2). 
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Figure 2. Non-Linear regression curves of the cytotoxicity of HuArgI (Co)-
PEG5000 (square) and HuArgI (Co)-PEG5000 + L-citrulline (triangle) on human 
GBM cell lines; 40 µM L-citrulline on:  U251 (A), U87-MG (B), T98 (C), HS683 
(D), SF (E), H4 (F), U118-MG (G), A172 (H) and SW1088 (I). 
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These results indicate that GBM cell lines are auxotrophic for arginine and 
sensitive to the HuArgI (Co)-PEG5000-induced arginine depletion as illustrated by 
in the inability of exogenous L-citrulline to rescue cells from arginine depletion-
induced cytotoxicity.  
 
3.2- Cell Cycle Analysis 
In addition to cytotoxicity, we determined the impact of HuArgI (Co)-
PEG5000-induced arginine depletion on the cell cycle of GBM cell lines. The cell 
cycle status of the panel of GBM cell lines was determined following 24 and 48 hour 
incubation with three different concentrations of the HuArgI (Co)-PEG5000 
(100000, 3000 and 45 pM) using PI staining. None of the cell lines tested showed 
any effect of HuArgI (Co)-PEG5000 treatment on cell cycle arrest at any 
concentration at both 24 and 48 h incubation. The fraction of cells in both the G0/G1 
and G2/M phases decreased with increasing HuArgI (Co)-PEG5000 concentrations. 
This was accompanied by an increase in the fraction of cells in the pre-G0/G1 phase 
at the highest concentrations of HuArgI (Co)-PEG5000, indicating that treatment 
induces complete cytotoxicity in the treated cells (Fig. 3A, B and C). The fraction of 
cells in the G0/G1 phase decreased from approximately 65% , 63% and 50% of the 
total cell population in control cells to approximately 44%, 41% and 45% of the 
surviving cell population, for the SF, T98 and U87 cell lines, respectively, following 
incubation with 100,000 pM of HuArgI (Co)-PEG5000 for 48 hours. This was 
associated with a corresponding decrease in the percentage of cells in the G2/M 
phase and an increase in the percentage of cells in the pre-G0/G1 phase (dead cells) 
from approximately 12%, 15% and 1% of the total cell population in control cells to 
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approximately 36%, 45% and 22% of the remaining cell population for SF, T98 and 
U87, respectively. 
A) 
  
B) 
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C) 
  
Figure 3. Cell cycle analysis of  SF (A), T98 (B) and U87 (C) cell line following 
treatment with HuArgI (Co)-PEG5000 for 48 h. Control cells are represented in the 
left panels and cells treated with 100 nM HuArgI (Co)-PEG5000 in the right panels. 
Cells are gated on width versus forward scatter (R1). Cells in G0/G1 are gated M1, 
G2/M are gated M2 and pre-G0/G1 (dead) are gated M3. All cell lines showed 
complete cell death following treatment, with no evidence of cell cycle arrest 
following 48 h of HuArgI (Co)-PEG5000-induced arginine depletion. 
 
The absence of cell cycle arrest following arginine deprivation in GBM cells 
further confirms the cytotoxicity of HuArgI (Co)-PEG5000-induced arginine 
depletion to these cells and demonstrates that the robust anti-proliferative effects 
observed in GBM cell lines are solely due to their cytotoxic response to arginine 
deprivation with no contribution of cell cycle arrest. 
 
3.3- Analysis of Cell Death  
In order to determine the type of cell death observed following HuArgI (Co)-
PEG5000-induced arginine depletion in GBM cells, we tested for annexin V/PI 
staining and caspase activation in our panel of GBM cell lines following 24 and 48 
hour incubation with three different concentrations of HuArgI (Co)-PEG5000 
20 
 
(100000, 3000 and 45 pM) using flow cytometry. Eight out of nine GBM cell lines 
tested (T98, U251, U87-MG, A172, HS683, H4, U118-MG and SW1088), showed 
an increase in the percentage of cells stained with both annexin V and PI, at both 24 
and 48 hours, following treatment with the highest concentration of HuArgI (Co)-
PEG5000 (100 nM) compared to controls, indicating either necrotic or late-stage 
apoptotic cell death (data not shown). Only one cell line, SF, stained positively for 
annexin V and negatively for PI indicating maintenance of membrane integrity, 
hence apoptotic cell death (Fig. 4A).  However, staining for active caspases revealed 
a total absence of caspase activation in all GBM cell lines tested, including SF, 
following treatment with HuArgI (Co)-PEG5000 for 24 and 48 h (Fig. 4B). 
 
A) 
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B) 
 
Figure 4. Analysis of the mechanism of HuArgI (Co)-PEG5000-mediated 
cytotoxicity in SF cells using annexin V/PI (A) and active caspase staining (B). SF 
cells incubated with 100 nM HuArgI (Co)-PEG5000 for 24 and 48 hours stained 
positively with both annexin V (FL1-H) and negatively with PI (FL2-H). Incubation 
of HuArgI (Co)-PEG5000-treated SF cells with a cell permeable, FITC-conjugated 
active caspase inhibitor revealed the absence of active caspases following incubation 
with HuArgI (Co)-PEG5000 (red) compared to non-treated cells (black). 
 
The absence of caspase activation, in addition to the loss of membrane 
integrity, in the majority of GBM cell lines, as evidenced by positive PI staining, 
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indicate that arginine depletion-induced cytotoxicity in AML cells is mediated 
through caspase-independent, non-apoptotic mechanisms. However, this analysis 
was complicated by the high fragmentation rate observed in GBM cells, following 
arginine depletion, which resulted in a limited population of analyzable cells. Hence, 
additional studies are needed to confirm the mechanism of cell death observed in 
GBM cell lines following treatment with HuArgI (Co)-PEG5000. 
 
3.4- Autopahgy Assay 
Amino acid depletion has been shown to be a potent activator of autophagy 
in a number of tumor types. Hence, we wanted to determine the contribution of 
autophagy to the arginine depletion-induced cyctotoxicity observed following 
treatment of GBM cells with HuArgI (Co)-PEG5000. Co-incubation of GBM cells 
with HuArgI (Co)-PEG5000 and the autophagy inhibitor chloroquine was performed 
to investigate the role of autophagy in the HuArgI (Co)-PEG5000-induced 
cytotoxicity of GBM. Four cell lines, namely, SF, A172, H4 and U251 were tested 
for sensitivity to HuArgI (Co)-PEG5000-induced arginine depletion in the  absence 
or presence of 10 µM chloroquine and, in all four cell lines, the addition of 
chloroquine (10 µM) induced a significant increase in the sensitivity of cells to 
HuArgI (Co)-PEG5000 at both 24 and 48 h incubation (Fig.5). The IC50 values 
obtained with the combination of HuArgI (Co)-PEG5000 and chloroquine were 
approximately 10 to 100-fold lower at 24 h and approximately 50 to 200-fold lower 
at 48 h, compared to IC50 values obtained with HuArgI (Co)-PEG5000 alone. Hence, 
inhibiting autophagy led to an increase in the sensitivity of GBM cells to arginine 
depletion, indicating that activation of autophagy, following arginine depletion, 
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plays a protective role against the HuArgI (Co)-PEG5000-induced cell death of 
GBM cells. 
 
Figure 5. Sensitivity of GBM cell lines to HuArgI (Co)-PEG5000 alone and in 
combination with the autophagy inhibitor chloroquine. Non-linear regression curves 
of SF at 24 hours, cells incubated with HuArgI (Co)-PEG5000 alone (square) or in 
combination with chloroquine (triangle). In the presence of chloroquine GBM cell 
lines were significantly more sensitive to HuArgI (Co)-PEG5000, at both 24 and 48 
h indicating the protective role played by chloroquine in arginine depletion-induced 
cell death. 
 
As expected, our results indicate that arginine depletion, following treatment 
of GBM cells with HuArgI (Co)-PEG5000, leads to the activation of autophagy, 
which seems to protect cells from arginine deprivation-induced cytotoxicity. 
 
3.5- Intracellular Staining and Flow Cytometry Analysis 
In order to investigate the underlying mechanisms of arginine auxotrophy in 
GBM cell lines and the sensitivity of these cells to HuArgI (Co)-PEG5000-induced 
arginine depletion, we determined the expression levels of argininosuccinate 
synthetase-1 (ASS-1) in our panel of GBM cell lines using single-cell intracellular 
staining on flow cytometry. Seven out of nine GBM cell lines (H4, U118-MG, 
HS683, U87-MG, T98, SF and U251) were positive for the expression of ASS-1 
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with RFI values of 7.76, 21.8, 2.38, 3.82, 2.18, 3.87 and 2.5, respectively (Fig.6 C, D 
and E, F, G, H and I). The remaining 2 cell lines (A172 and SW1088) were negative 
for the expression of ASS-1 as illustrated by RFI values of 1.28 and 1.76, 
respectively (Table 2, Fig.6 A and B). 
 
Table 2. Sensitivity of GBM cell lines to HuArgI (Co)-PEG5000 both in the absence 
and presence of  1.14µM of exogenous L-citrulline in addition to ASS-1 expression. 
 
Cell line HuArgI (Co)-
PEG5000 
HuArgI (Co)-
PEG5000 + L-
citrulline 
ASS-1 expression 
U251 128 pM 134 pM Positive 
U87-MG 152 pM 145 pM Positive 
T98 204 pM 751 pM Positive 
HS683 312 pM 347 pM Positive 
SF 325 pM 255 pM Positive 
H4 329 pM 343pM Positive 
U118-MG 442 pM 874 pM Positive 
A172 981 pM 706 pM Negative 
SW1088 985 pM 581 pM Negative 
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Furthermore, analysis of the percentage of ASS-1 positive cells, in the panel 
of GBM cell lines (forward scatter versus FL1-H) revealed that, in the two cell lines 
that were negative for ASS-1 expression based on ratio of fluorescence intensity 
(RFI) (SW1088 and A172), less than 25% of the total cell population was positive 
for the expression of ASS-1. On the other hand, the percentage of cells positive for 
the expression of ASS-1 ranged from 44% to 88% of the total cell population in the 
6 GBM cell lines that were positive for the expression of ASS-1 based on ratio of 
fluorescence intensity (RFI).  
 
A) 
 
B) 
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G) 
 
H) 
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Figure 6. Staining of argininosuccinate synthetase-1 (ASS-1) in 9 AML cell lines, 
SW1088 (A), A172 (B), H4 (C), U118-MG (D), HS683 (E), U87-MG (F), T98 (G), 
SF (H) and U251 (I) using single-cell intracellular staining on flow cytometry. 
SW1088 and A172 were negative for ASS1 presence as shown by a ratio of 
fluorescence intensity (RFI) of 1.78 and 1.28, respectively, between cells stained for 
ASS1 (grey) and cells incubated with an isotype control (black). H4, U118-MG, 
HS683, U87-MG, T98, SF and U251 were positive for ASS-1 expression with RFI > 
2. Cells are gated on width versus forward scatter (R1). 
 
The presence of ASS-1 in 7 out of 9 GBM cell lines tested indicates that 
these cells may be partially auxotrophic for arginine and that the underlying 
mechanism for their sensitivity to HuArgI (Co)-PEG5000-induced arginine depletion 
is also partially due to their high replication rate. The failure of exogenous L-
citrulline (1.14 µM) to reverse cytotoxicity of GBM cells following arginine 
depletion, though indicative of complete arginine auxotrophy, may, in this case, also 
underlie the marked arginine dependency of GBM cell lines. The only 2 cell lines 
that were partially rescued by the addition of 1.14 µM of L-citrulline (U118-MG and 
T98) were both positive for the expression of ASS1. 
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CHAPTER FOUR 
DISCUSSION 
Compared to other tumor types, GBM is considered an aggressive cancer 
since it is very resilient and resistant to conventional chemotherapy and is associated 
with very low survival rates that do not exceed one year, on average (Mischel & 
Cloughessi, 2003). Thus finding novel targeted therapies for GBM has become of 
vital importance. 
In this study, we have shown that Glioblastoma (GBM) cells are auxotrophic 
for arginine and, thus, sensitive to the HuArgI (Co)-PEG5000-induced arginine 
depletion since the entire panel of GBM cell lines was sensitive to HuArgI (Co)-
PEG5000 with IC50 values in the
 
pM range, indicating the high potency of arginine 
deprivation in GBM cell lines. Moreover, complete arginine dependence of GBM 
cells was demonstrated as cells did not recover from the cytotoxic effects of HuArgI 
(Co)-PEG5000-induced arginine depletion after the addition of exogenous L-
citrulline at a concentration of 1.14 µM.  Exogenous L-citrulline failed to rescue any 
of the GBM cell lines tested from the HuArgI (Co)-PEG5000-induced cytotoxicity 
and only slightly decreased the sensitivity of two GBM cell lines, T98 and U118-
MG, by up to 3-fold compared to cells treated with HuArgI (Co)-PEG5000 alone. 
We will further test selectivity of arginine deprivation-induced cytotoxicity to GBM 
cells by determining the impact of arginine deprivation on a number of normal 
human cells and tissues. Previous studies have demonstrated the selectivity of 
arginine deprivation to tumor cells and its potential as targeted therapy by showing 
the lack of arginine auxotrophy of a panel of normal cells and their resistance to 
arginine deprivation (Agrawal et al, 2012). Potential arginine auxotrophy of GBM 
cells and the possibility of targeting GBM through arginine deprivation therapy have 
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not been investigated yet. To our knowledge, this is the first study to examine amino 
acid deprivation in general and arginine deprivation in particular for the targeting of 
GBM. 
Sensitivity of cells to arginine deprivation may be due solely to complete 
arginine auxotrophy (total lack of ASS-1 expression) or to a combination of partial 
arginine auxotrophy (low expression of ASS-1) coupled to a high cellular 
proliferation rate, rendering cells dependent on extracellular sources of arginine. 
Addition of excess, exogenous L-citrulline is commonly used to differentiate 
between complete and partial arginine auxotrophy with the ability of exogenous L-
citrulline to rescue cells from arginine-deprivation induced cell death being 
considered an indication of partial arginine auxotrophy (Mauldin et al, 2012). Cells 
with a total lack of ASS-1 expression would not be rescued by additional L-
citrulline, hence the complete arginine auxotrophy. The inability of the exogenous L-
citrulline to rescue GBM cells from arginine-deprivation induced cytotoxicity does 
not rule out partial auxotrophy since we have only used a single concentration of L-
citrulline. We are planning to increase the concentration of L-citrulline, by 10-fold 
increments, to cover a range from 1.14 µM to 11.4 mM, in order to determine the 
degree of arginine auxotrophy of GBM cell lines. 
Arginine auxotrophy and sensitivity to arginine deprivation have been 
demonstrated in a number of tumor types including melanoma, hepatocellular 
carcinoma (HCC), renal cell carcinoma (RCC), prostate cancer and acute lymphoid 
leukemia (T-ALL). Several studies have shown that these tumor types are sensitive 
to arginine depletion-induced cytotoxicity following treatment with human arginase 
or with bacterial arginine deiminase demonstrating that amino acid deprivation in 
auxotrophic tumors is a novel targeted therapy (Cheng, 2008; Kim, 2009; Manca, 
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2011) In this study, we are the first to show that GBM cells can be potentially 
targeted by arginine deprivation using a recombinant human arginase, HuArgI (Co)-
PEG5000. 
We have also investigated the expression levels of arginosuccinate synthetase 
1 (ASS-1) in GBM cell lines in an attempt to determine the underlying mechanisms 
of arginine auxotrophy and sensitivity to HuArgI (Co)-PEG5000-induced arginine 
depletion of GBM cells. Intracellular staining and flow cytometry analysis revealed 
that only 2 out of the panel of 9 GBM cell lines tested were negative for the 
expression of ASS-1 (RFI ≤ 2) with the remaining 7 cell lines showing a wide range 
of ASS-1 expression (RFI > 2). These results are surprising since the sensitivity of 
GBM cells to HuArgI (Co)-PEG5000-induced arginine depletion along with the 
inability of exogenous L-citrulline to rescue cells from arginine deprivation-induced 
cytotoxicity had suggested complete arginine auxotrophy of GBM cells. The pattern 
of ASS-1 expression rather suggests that the majority of GBM cell lines are partially 
auxotrophic for arginine with their sensitivity to arginine deprivation being due to a 
combination of partial auxotrophy and rapid replication rates. This will be tested by 
the addition of higher concentrations of exogenous L-citrulline (up to 11.4 mM) as 
described earlier. The intracellular staining and flow cytometry analysis method used 
to determine ASS-1 expression in GBM cells is a qualitative method that determines 
whether or not the cells express ASS-1 with no quantitative indication of the levels 
of ASS-1 expression in each cell line. The ratio of fluorescence intensity (RFI), the 
measure of positivity, is dependent on the number of cells that stain positively for 
ASS-1 compared to cells stained with the isotypic control. Hence, it is possible that 
even cell lines shown positive for ASS-1 expression by this method have very low 
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ASS-1 expression levels in each individual cell rendering them completely 
auxotrophic for arginine. 
 
Furthermore, we have assessed the effect of arginine induced depletion on 
the cell cycle of GBM cells. None of the GBM cells tested showed cell cycle arrest 
following HuArgI (Co)-PEG5000-induced arginine depletion confirming the 
cytotoxicity of arginine deprivation to GBM cells and indicating that the robust 
decrease in proliferation observed following ariginine deprivation is solely due to the 
cytotoxicity of HuArgI (Co)-PEG5000 to GBM cells with no contribution of cell 
cycle arrest.  
Moreover, analysis of the mechanism of cell death showed potential signs of 
apoptotic cell death in GBM cells following HuArgI (Co)-PEG5000-induced 
arginine depletion. One of the GBM cell lines tested was positive for annexin V 
staining while maintaining membrane integrity (Negative PI staining) following 
treatment with HuArgI (Co)-PEG5000. However, none of the other cell lines tested 
showed similar results with all being positive for both annexin V and PI staining 
indicating loss of membrane integrity. In addition, we were unable to show caspase 
activation in any of the GBM cell lines tested following HuArgI (Co)-PEG5000-
induced arginine deprivation indicating that cell death following arginine deprivation 
in these cells is caspase-independent. Our findings at this point are inconclusive and 
do not allow us to confirm that HuArgI (Co)-PEG5000-induced arginine depletion 
causes apoptotic cell death in GBM cell lines. 
 Other studies have shown that arginine depletion induces apoptosis in a 
number of tumor types, including hepatocellular and pancreatic carcinoma (Glazer et 
al, 2010). Further studies will be carried out to determine the type of cell death 
observed in GBM cell lines.  
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Autophagy, a rather novel aspect of tumor cell response to treatment, has 
been widely tested following anti-cancer therapies. The contribution of autophagy to 
the response of the different types of tumor cells to the various therapeutic agents is 
being increasingly investigated and its impact has been demonstrated in several 
tumor types. For the first time, in this study, the contribution of autophagy is 
investigated following an amino acid depletion therapy. Following HuArgI (Co)-
PEG5000-induced arginine depletion; autophagy was shown to play a protective role 
during arginine deprivation. The disruption of the autophagolysososmes and the 
subsequent inhibition of autophagy in GBM cells, following the addition of 
chloroquine, led to an increase in the cells' sensitivity to the arginine depletion by 
several folds ultimately leading to accelerated cell death. Such findings suggest that 
autophagy is activated following HuArgI (Co)-PEG5000-induced arginine depletion 
in GBM cells and that it plays a protective role against arginine deprivation-induced 
cell death. 
In this study, we have demonstrated that GBM cell lines are auxotrophic for 
arginine and the potential use of such aspect to target cancerous cells by the use of 
HuArgI (Co)-PEG5000-induced arginine depletion. Moreover, we have shown that 
GBM cells can be protected from arginine deprivation-induced cytotoxicity by 
activating autophagy. HuArgI (Co)-PEG5000 is, therefore, a novel potent and 
potentially selective treatment for glioblastoma. 
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